Kwality Pharmaceuticals Limited Q1 FY27 earnings call summary

Earnings call of 10 Aug 2026, summarised by AI from the filing.

Kwality Pharmaceuticals guides FY27 revenue above ₹700 cr with 26% to 27% EBITDA margin; Q1 gross margin was 53%.

Key takeaways

1. Gross margin 53% in Q1 FY27, against roughly 56% or 57% in the previous quarter, which management still described as an improvement.
2. FY27 guidance Revenue guided above ₹700 cr with EBITDA margin of 26% to 27% for FY27.
3. Working capital Debtor days to fall from 208 days to 165-170 days.
4. Registrations 60-70 registrations over the last three quarters, each adding roughly 1.5 million to 2 million in yearly sales.
5. Approval risk Delays at other countries' health ministries can affect the sales targets given.

Original filing on BSE

Kwality Pharmaceuticals Limited earnings call, investor presentation and press release summaries

• Q1 FY27: Earnings call (10 Aug 2026), Results deck (10 Aug 2026)
• Q4 FY26: Earnings call (19 May 2026), Results deck (19 May 2026)
• Q3 FY26: Results deck (12 Feb 2026)
• Q4 FY25: Results deck (5 Jun 2025)